期刊
JOURNAL OF DAIRY SCIENCE
卷 105, 期 4, 页码 2791-2802出版社
ELSEVIER SCIENCE INC
DOI: 10.3168/jds.2021-21247
关键词
SARS-CoV-2 in the future; lactoferrin; SARS-CoV-2; variants of concern
资金
- University of Michigan Institute for Clinical and Health Research (MICHR)
- National Center for Advancing Translational Science [UL1TR002240]
- Center for Drug Repurposing
- National Institute of Diabetes and Kidney Diseases [R01DK120623]
- University of Michigan Pharmacological Sciences Training Program (PSTP) [T32]
Bovine lactoferrin (bLF), a naturally occurring glycoprotein found in milk, has been found to strongly inhibit SARS-CoV-2 infection through direct entry inhibition and immunomodulatory mechanisms. This study shows that bLF is effective against different strains of the virus, including the B.1.1.7 variant. The study also highlights the potential of lactoferrin as a clinical candidate for the treatment or prevention of SARS-CoV-2.
Bovine lactoferrin (bLF), a naturally occurring glycoprotein found in milk, has bioactive characteristics against many microbes, viruses, and other pathogens. Bovine lactoferrin strongly inhibits SARS-CoV-2 infection in vitro through direct entry inhibition and immunomodulatory mechanisms. This study reports on the anti-SARS-CoV-2 efficacy of commercially available bLF and common dairy ingredients in the human lung cell line H1437 using a custom high-content imaging and analysis pipeline. We also show for the first time that bLF has potent efficacy across different viral strains including the South African B.1.351, UK B.1.1.7, Brazilian P.1, and Indian Delta variants. Interestingly, we show that bLF is most potent against the B.1.1.7 variant [half-maximal inhibitory concentration (IC50) = 3.7 mu g/mL], suggesting that this strain relies on entry mechanisms that are strongly inhibited by bLF. We also show that one of the major proteolysis products of bLF, lactoferricin B 17-41, has a modest anti-SARS-CoV-2 activity that could add to the clinical significance of this protein for SARS-CoV-2 treatment as lactoferricin is released by pepsin during digestion. Finally, we show that custom chewable lactoferrin tablets formulated in dextrose or sorbitol have equivalent potency to unformulated samples and provide an option for future human clinical trials. Lactoferrin's broad inhibition of SARS-CoV-2 variants in conjunction with the low cost and ease of production make this an exciting clinical candidate for treatment or prevention of SARS-CoV-2 in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据